4.5 Article

MicroRNA-335-5p and-3p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance

Journal

FEBS LETTERS
Volume 591, Issue 2, Pages 382-392

Publisher

WILEY
DOI: 10.1002/1873-3468.12538

Keywords

breast cancer; endocrine resistance; estrogen receptor; isoform; microRNA; miRNA-335

Funding

  1. National Institutes of Health [CA125806, CA174785]
  2. Office of Naval Research [N00014-16-1-1136]
  3. National Center for Research Resources [P20RR020152]
  4. Department of Defense Breast Cancer Research Program [BC085426, NCI-U54 CA113001-07]
  5. National Institute of General Medical Sciences of the National Institutes of Health [U54 GM104940]
  6. NATIONAL CANCER INSTITUTE [R01CA174785, U54CA113001, R01CA125806] Funding Source: NIH RePORTER
  7. NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020152] Funding Source: NIH RePORTER
  8. NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM104940] Funding Source: NIH RePORTER

Ask authors/readers for more resources

microRNAs (miRNAs) are small noncoding RNA molecules involved in the regulation of gene expression and play critical roles in human malignancies. Next-generation sequencing analysis of the MCF-7 breast cancer cell line overexpressing miR-335-5p and miR-335-3p demonstrated that the miRNA duplex repressed genes involved in the ERa signaling pathway, and enhanced resistance of MCF-7 cells to the growth inhibitory effects of tamoxifen. These data suggest that despite its conventional role in tumor suppression, the miR-335 transcript can also play an oncogenic role in promoting agonistic estrogen signaling in a cancerous setting.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available